NanoViricides Inc
NNVC
查看详细走势图
1.250USD
+0.040+3.31%
收盘 12/19, 16:00（美东）报价延迟15分钟
21.95M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.31%
5天
0.00%
1月
+0.81%
6月
-12.59%
今年开始到现在
-12.59%
1年
-16.11%
查看详细走势图
TradingKey NanoViricides Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
NanoViricides Inc当前公司基本面数据相对谨慎，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名227/404位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价7.00。中期看，股价处于下降通道。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
NanoViricides Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
7.000
目标均价
+389.51%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
NanoViricides Inc亮点
亮点风险
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
估值低估
公司最新PE估值-2.47，处于3年历史低位
机构减仓
最新机构持股1.34M股，环比减少14.11%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值605.58K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.42
NanoViricides Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
NanoViricides Inc简介
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
公司代码NNVC
公司NanoViricides Inc
CEODiwan (Anil)
网址https://www.nanoviricides.com/
常见问题
NanoViricides Inc(NNVC)的当前股价是多少？
NanoViricides Inc(NNVC)的当前股价是 1.250。
NanoViricides Inc的股票代码是什么？
NanoViricides Inc的股票代码是NNVC。
NanoViricides Inc股票的52周最高点是多少？
NanoViricides Inc股票的52周最高点是2.230。
NanoViricides Inc股票的52周最低点是多少？
NanoViricides Inc股票的52周最低点是0.940。
NanoViricides Inc的市值是多少？
NanoViricides Inc的市值是21.95M。
NanoViricides Inc的净利润是多少？
NanoViricides Inc的净利润为-9.47M。
现在NanoViricides Inc(NNVC)的股票是买入、持有还是卖出？
根据分析师评级，NanoViricides Inc(NNVC)的总体评级为--，目标价格为7.000。
NanoViricides Inc(NNVC)股票的每股收益（EPS TTM）是多少
NanoViricides Inc(NNVC)股票的每股收益（EPS TTM）是-0.503。
相关品种
